Transthyretin Amyloidosis (ATTR)

American Heart Association (AHA) 2026

Congress Details

November 7-9, 2026

Chicago, IL, USA

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Agenda

07 November, 2026

Sex Differences at Diagnosis Among Patients With Hereditary or Wild-Type Transthyretin Amyloidosis Analysis From the ConTTRibute Study

Presentation Type

Poster

Time

10:30 CST

Location

Poster #4012 Science and Technology Hall, South Hall, Level 3

Title

Sex Differences at Diagnosis Among Patients With Hereditary or Wild-Type Transthyretin Amyloidosis: Analysis From the ConTTRibute Study

Presenter

Zubair Shah

University of Kansas
KS, USA

09 November, 2026

2-Year Results From the Open-Label Extension Period of the Phase 3 HELIOS-B Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Presentation Type

Presentation

Time

9:40 CST

Location

Learning Studio 2, Science and Technology Hall, South Hall

Title

2-Year Results From the Open-Label Extension Period of the Phase 3 HELIOS-B Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Presenter

Sarah Cuddy

Brigham and Women's Hospital
MA,USA